A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

NCT02193776 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis

Interventions

DRUG: PA-824
DRUG: bedaquiline
DRUG: moxifloxacin
DRUG: pyrazinamide
DRUG: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet

Sponsor

Global Alliance for TB Drug Development